Boehringer Ingelheim to present new drug data at ATS conference

Boehringer Ingelheim has announced that it will be attending the American Thoracic Society (ATS) International Conference later this month, where it will share its latest drug research findings.

Taking place from May 16th to 21st 2014 in San Diego, the event gives the company an opportunity to present phase III trial data on new therapies for idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

Initial results of the two confirmatory INPULSIS trials will underline the efficacy and safety of nintedanib in the treatment of IPF, a rare, debilitating and fatal lung disease that remains relatively unknown.

Meanwhile, data from the TOviTO trial programme will demonstrate the benefits of using a tiotropium plus olodaterol fixed-dose combination as a new option for COPD sufferers.

Professor Klaus Dugi, chief medical officer at Boehringer Ingelheim, said the presentation "marks another important milestone in our goal of developing innovative therapies to address the unmet medical needs in COPD".

This come after the firm last week received a European Committee for Medicinal Products for Human Use recommendation for its anticoagulant Pradaxa to be approved as a treatment for deep vein thrombosis and pulmonary embolism.